Introduction Chordomas are rare primary tumours of the skull base, spine, and sacral-coccygeal bones [1]. Surgery and radiotherapy are the standard of care as there are no FDA-approved therapeutic agents. Some (40%) of these tumours metastasise, and the median survival of 7 years has not improved significantly in several decades [2]. Chordomas show notochordal differentiation and are hypothesised to arise from the notochord [3, 4], which is the defining feature of the chordate phylum.
